ImageneBio (IMA) Capital Expenditures (2020 - 2023)
ImageneBio (IMA) posted Capital Expenditures of $262000.0 for Q4 2023, up 72.37% sequentially from $152000.0 in Q1 2023, and up 13.42% YoY from $231000.0 in Q4 2022.
ImageneBio (IMA) Capital Expenditures (2020 - 2023) Analysis & Trends
ImageneBio has reported Capital Expenditures for 4 years, with the latest figure at $262000.0 in Q4 2023.
- Quarterly Capital Expenditures rose 13.42% year-over-year to $262000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $414000.0 (down 71.07% YoY) and the FY2023 annual result came in at $414000.0, down 71.07% from the prior year.
- Capital Expenditures advanced to $262000.0 in Q4 2023 per IMA's latest filing, from $152000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $910000.0 in Q2 2022 and troughed at -$1000.0 in Q2 2020.
- A 4-year average of $312214.3 and a median of $209000.0 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures surged 18800.0% in 2021, then slumped 96.07% in 2022.
- Over 4 years, Capital Expenditures stood at $638000.0 in 2020, then dropped by 13.79% to $550000.0 in 2021, then sank by 58.0% to $231000.0 in 2022, then climbed by 13.42% to $262000.0 in 2023.
- According to Business Quant data, Capital Expenditures over the past three periods registered $262000.0, $152000.0, and $231000.0 for Q4 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 262,000.00 |
| Dec 31, 2023 | 262,000.00 |
| Mar 31, 2023 | 152,000.00 |
| Mar 31, 2023 | 152,000.00 |
| Dec 31, 2022 | 231,000.00 |
| Dec 31, 2022 | 231,000.00 |
| Sep 30, 2022 | 257,000.00 |
| Sep 30, 2022 | 257,000.00 |
| Jun 30, 2022 | 910,000.00 |
| Jun 30, 2022 | 910,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | 550,000.00 |
| Dec 31, 2021 | 550,000.00 |
| Sep 30, 2021 | 184,000.00 |
| Sep 30, 2021 | 184,000.00 |
| Jun 30, 2021 | 187,000.00 |
| Jun 30, 2021 | 187,000.00 |
| Mar 31, 2021 | 839,000.00 |
| Mar 31, 2021 | 839,000.00 |